Immune-Related Adverse Events After First-Line Immunotherapy for Metastatic NSCLC
A 67-year-old former smoker with metastatic lung adenocarcinoma (PD-L1 TPS 70%, no driver mutations) began pembrolizumab monotherapy 3 weeks ago. He now presents with 4 days of progressive dyspnea, a dry cough, and fatigue. Oxygen saturation is 89% on room air; he is afebrile. CT shows new bilateral ground-glass opacities without consolidation or effusion. He is on no antibiotics. His oncologist is away, and the covering resident must decide whether this is infection or immune-related pneumonitis, and whether to continue or hold immunotherapy.
1. How should the resident distinguish immune-related pneumonitis from infection, and what is the immediate management?
Read the worked answer
The presentation - subacute dyspnea, dry cough, hypoxia, afebrile, bilateral ground-glass opacities, and recent anti-PD-1 therapy - is classic for immune-related pneumonitis, though infection cannot be excluded. The resident should:
- Hold pembrolizumab immediately. Do not give the next dose until the diagnosis is clarified.
- Grade the toxicity: hypoxia with SpO₂ 89% on room air corresponds to at least grade 3 pneumonitis, which mandates high-dose corticosteroids.
- Start IV methylprednisolone 1–2 mg/kg/day (or equivalent) without waiting for a definitive diagnosis if hypoxia is significant, while simultaneously covering for infection with empiric antibiotics and sending blood cultures, sputum, and viral PCRs including CMV and Pneumocystis.
- Do not delay steroids for bronchoscopy; bronchoscopy with BAL can help exclude infection but should not delay treatment in a hypoxic patient.
- Involve pulmonology and consider ICU if oxygen requirements escalate.
Key point: immune-related pneumonitis is a diagnosis of exclusion but is treated empirically when the clinical picture fits, because delay increases mortality.
2. He improves on steroids. Outline the steroid taper, the criteria for restarting or permanently discontinuing immunotherapy, and the role of alternative immunosuppression.
Read the worked answer
Taper: After clinical and radiographic improvement, taper prednisone over at least 4–6 weeks; rapid tapers cause rebound pneumonitis. Monitor oxygen saturation and repeat imaging before completing the taper.
Restarting: For grade 3 pneumonitis, permanent discontinuation of anti-PD-1/PD-L1 therapy is generally recommended; rechallenge carries a high risk of recurrence and is reserved for carefully selected patients after full resolution and shared decision-making. Because his tumor has PD-L1 TPS 70%, he had a high chance of benefit, so the discussion should weigh the risk of recurrent pneumonitis against the loss of a highly effective therapy.
Alternative immunosuppression: If steroids fail or the patient cannot taper below a high dose, add infliximab or mycophenolate mofetil; cyclophosphamide is reserved for refractory cases. Prophylaxis for Pneumocystis and bone protection should be considered during prolonged steroids. Document the event and counsel the patient to report dyspnea promptly if any future immunotherapy is considered.